美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Virtus LifeSci Biotech Products ETF

102.00

+0.86060.85%

盤後：101.73-0.2698-0.26%19:30 EDT

成交量：6,836

成交額：69.80萬

市值：1.22億

市盈率：- -

高：102.80

開：102.09

低：101.14

收：101.14

52周最高：110.05

52周最低：68.05

股本：120.00萬

流通股本：120.00萬

量比：0.72

換手率：0.57%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

特朗普：美國利率應降至1%或更低

特朗普社媒动态

白宮稱聯儲局加息舉措「相當令人遺憾」

五張圖表揭示市場對聯儲局決議的即時反應

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業

特朗普：8月就業數據超預期，要求聯儲局降息

特朗普社媒动态

康寧傑瑞生物製藥回購56,000股耗資492,430港元

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

武漢友芝友生物製藥股份有限公司在香港暫停交易。

新股消息 | 貝達藥業(300558.SZ)再度遞表港交所「四駕馬車」協同打造全產業鏈生物製藥

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

海正藥業與星際開發達成戰略合作佈局太空生物製藥

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

阿巴斯生物製藥宣佈擬通過改良式「荷蘭拍賣」要約收購，回購最高價值2.3億美元的公司普通股。

駿利亨德森投資：專利到期倒逼藥企擴張生物科技併購、IPO市場同步復甦

智通财经网

杭蕭鋼構等投資成立生物製藥公司

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BBP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":101.9998,"timestamp":1789588800000,"preClose":101.1392,"halted":0,"volume":6836,"hourTrading":{"tag":"盘后","latestPrice":101.73,"preClose":101.9998,"latestTime":"19:30 EDT","volume":32,"amount":3268.2282,"timestamp":1789601403689,"change":-0.2698,"changeRate":-0.002645,"amplitude":0},"delay":0,"changeRate":0.008509064734543983,"floatShares":1200004,"shares":1200004,"eps":0,"marketStatus":"未開盤","change":0.8606,"latestTime":"09-16 16:00:00 EDT","open":102.09,"high":102.8,"low":101.14,"amount":698003.58872,"amplitude":0.016413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":101.1392,"sharesOutstanding":600004,"nav":101.285,"aum":121542550.39,"bidAskSpread":0.002402,"postHourTrading":{"tag":"盘后","latestPrice":101.73,"preClose":101.9998,"latestTime":"19:30 EDT","volume":32,"amount":3268.2282,"timestamp":1789601403689,"change":-0.2698,"changeRate":-0.002645,"amplitude":0},"volumeRatio":0.718626,"impliedVol":0.2281,"impliedVolPercentile":0.4622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1200004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.718626,"shares":1200004,"dividePrice":0,"high":102.8,"amplitude":0.016413,"preClose":101.1392,"low":101.14,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":101.9998,"eps":0,"divideRate":0,"volume":6836,"delay":0,"ttmEps":0,"open":102.09,"prevYearClose":79.9149,"prevWeekClose":103.4597,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":105.5207,"twentyDayClose":103.4785,"sixtyDayClose":91.6325},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116160811","title":"特朗普：美國利率應降至1%或更低","url":"https://stock-news.laohu8.com/highlight/detail?id=1116160811","media":"特朗普社媒动态","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116160811?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 04:38","pubTimestamp":1789591115,"startTime":"0","endTime":"0","summary":"美国总统特朗普9月16日在X平台发帖，要求将美国利率降至1%或更低。特朗普称，美国拥有全球最好的信用，“遥遥领先”，且国家正因新投资而繁荣。他主张，如果美国停止与所有存在贸易逆差的国家进行贸易——这些国家占大多数——每年可以赚取至少1.5万亿美元。特朗普将“赤字”定义为“损失”的别称，并指责美国“背负”了世界上几乎所有的国家，这种情况不能持续下去。他在帖文最后强调：“为美利坚合众国降低利率，而且要快！”。\n特朗普的言论延续了他长期以来对美联储加息政策的批评。此前他在竞选期间曾多次呼吁降低利率以刺激经济。目前美联储联邦基金利率目标区间为5.25%至5.5%。\n","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","07522","TSDD","SMAX","TQQQ","SDS","SPXS","03455","NOCT","AVSD","KOMP","07261","QQQX","SSO","02834","03086","UPRO","SPDN","RJZ","TSII","TSLP","TESC","03034","07366","07766","TSLL","TSL","SPUU","IJK","TSLS","HEEM","TSLW","NJUL","CGDV","ANEW","BBP","SH","09366","SCEP","SPYQ","TSLY","QQQM","SHUS","09766","07266","LQDH","DMAX","OVS","SQQQ","ELOL","TSLZ","LQDB","NAPR","07568","TSLR","SPY","AMHI","SPYU","QMAR","CLIX","GPIQ","TSYY","CAOS","TSLT","HIBL","SPXL","HYXF","QQQ","PEVC","YSPY","CRSH","RVRB","FXL","DFUV","BK4585","NJAN","IBCB","QLD","SPYH","JA","TSLQ","TSLI","THIR","TLA","TSLO","SPXU","SPYM","FXR","TEST","LRCY","TSLG","UCC","VAW","09086","VOO","IVV","VPX","09834","QDEC","MMAX","QID","TQQY","PSQ","TESL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163308609","title":"白宮稱聯儲局加息舉措「相當令人遺憾」","url":"https://stock-news.laohu8.com/highlight/detail?id=1163308609","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163308609?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 03:51","pubTimestamp":1789588269,"startTime":"0","endTime":"0","summary":"白宫发言人库什·德赛表示，美联储决定上调利率一事“相当令人遗憾”。德赛在福克斯新闻的一次访谈中指出：“我认为总统在利率走向上的立场已表达得极为明确。而今天，美联储选择加息，从政府的视角来看，这一决定实在缺乏足够有说服力的经济依据来支撑。”他进一步补充道：“这已不是拜登执政的时代了。总统和共和党人并未像民主党与乔·拜登那样，斥资数万亿美元用于新冠疫情刺激计划。我们并不存在那种需要通过抬升利率来遏制失控的总需求。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLO","UCC","07366","BK4588","TESL","TSII","ELOL","TSLZ","AVSD","RJZ","LRCY","TSLR","TSLS","IJK","TLA","07766","TSLP","TSLT","CGDV","FXL","VAW","PEVC","CAOS","CRSH","TSLL","KOMP","09366","DFUV","TESC","BK4585","TSLQ","TEST","TSYY","TSLY","TSLW","TSLG","TSL","09766","TSLI","ANEW","BBP","CLIX","TSDD","FXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182814613","title":"五張圖表揭示市場對聯儲局決議的即時反應","url":"https://stock-news.laohu8.com/highlight/detail?id=1182814613","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182814613?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 02:37","pubTimestamp":1789583865,"startTime":"0","endTime":"0","summary":"美联储自2023年以来首次宣布加息，这一重磅决策立刻在金融市场激起层层涟漪。投资者们屏息凝神，紧盯着各类资产价格的风向变化，试图捕捉每一个微妙的信号。从股市到债市，从美元汇率到大宗商品，无不呈现出耐人寻味的波动轨迹。整体来看，这五张图表勾勒出一幅市场在政策转向之际既紧张又充满算计的生动图景，每一根K线、每一个波动点都在诉说着投资者对未来利率路径的重新定价。","market":"us","thumbnail":"https://static.tigerbbs.com/1c0b4eef7036bef961440319a6488bce","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1c0b4eef7036bef961440319a6488bce"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHY","UBT","TLTX","JPO","09086","XBFR","TSLW","NOCT","DBND","ISSXF","09766","BBLB","FXR","QQQX","SGRT","LVLN","UDN","US6M.BOND","TSLZ","VGIT","BUFH","SGOV","LQD","VEXC","02834","HYGU","HYIN","FT","SIXH","IGOV","TSLO","US2Y.BOND","MUNX","07266","EOPS","BK4535","IEF","NJAN","RAUS","07522","CPNM","XLF","PAYH","TSLY","IEI","CIVG","US3Y.BOND","CDIG","VGLT","RULE","HIDV","VGSH","QID","VTV","EQRR","KBE","NJUL","EMPB","SSEUF","OGSP","JULD","TSLS","AMZU","OOQB","KOMP","MYCN","QQQM","TESL","AMZD","BK4561","BWX","US5Y.BOND","AMZZ","JADB","TIP","UCC","IAT","JPST","WAMA","FDLO","FXL","KHPI","AMZW","ATTR","DVUT","FLSP","OCTU","TSYY","WLDR","BOXX","FLDZ","NAPR","MYCI","NQLT","US12M.BOND","PTLC","KRX","QLDY","SLTY","JPMO","AMAA","AMZO","BBP","BK4581","QIS","KBWB","TYO","TSLT","BK4593","VCIT","SPBW","RORO","07568","AMZP","AMZG","SCHO","BGH","CRSH","LIAJ","ZSEP","TSLQ","BINT","TBIL","GDMA","QLD","KRE","TEST","TSLR","VCSH","BSV","BAMA","AVSD","HAWG","SDHY","TBT","TSDD","NELS","DADS","PLGI","EDV","VOOV","ARKD","LQDU","TSYW","ZAPR","ELOL","JOYT","NSCI","PRIV","QQQ","EIM","FAZ","ANEW","IJK","KOOL","OOSP","RGLO","ZBmain","BWZ","CGDV","GBIL","HYG","03455","PBDC","UBmain","BBIB","BK4504","AZYY","07766","SCLZ","TBJL","TLT","TSLI","TQQQ","SKRE","BK4588","TQQY","HF","BKIV","DBMF","RAAA","TSL","VFH","SOVF","TMF","ZTmain","PEMX","TSLL","BND","USHY","ZROZ","MDPL","GXDW","FITZ","HFEQ","ABUF","CAOS","EBND","NGHT","PEVC","US10Y.BOND","XLRI","DPST","PSQ","BAMO","RJZ","XBIL","DFUV","LQDD","SPBX","US30Y.BOND","BBSB","AAUB","LQ","MUB","09366","07366","ISHG","APOC","07261","SHV","VAW","LALT","BIL","EQIN","ITDH","PBQQ","FARX","BCFN","BOND","TLTW","UUP","09834","MFMO","TLH","QMAR","03086","FLGV","RSBA","BK4550","OCTM","QDEC","TSII","TFJL","AGG","SQQQ","TESC","TSLG","AMZY","IALT","MINT","TSLP","BK4585","ZFmain","GOLY","CLIX","GOVT","TLA","US7Y.BOND","03034","LRCY","QUSA","HYGD","GPIQ","NEMD","TNmain","TLTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","SYNB","LU2322448791.USD","TMED","LFSC","HELX","LU1992135399.USD","PBE","BK4585","FTXH","BBH","CANC","LU2272731600.USD","LU2272731865.HKD","RSPH","PSCH","IBB","IDNA","IEIH","MRNY","XBIX","BK4588","FBT","BME","RXL","AZNH","LU2322448957.HKD","PJP","XPH","IEHS","LU2272731782.SGD","WDNA","IBRN","BIOY","LU2473716301.USD","IYH","MEDI","IE00B5TLWC47.USD","BBP","MRNX","LU1992135472.HKD","BIB","PPH","PBPH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["FXH","PBPH","PJP","IHE","TMED","TRUH","BBP","159839","RSPH","MEDI","APXH","BME","JDOC","IYH","BBH","PPH","GSKH","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"復宏漢霖朱儁：未來所有製藥企業都是AI製藥企業，不存在不依賴AI的生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665936888?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306701.USD","HK0000306685.HKD","02696","03069","HK0000320264.USD","IBBQ","MRNY","AGIX","QTOC","AIPO","BK1161","BBP","BK1191","BK1574","ARTY","HK0000320223.HKD","MRNX","CHAT","VTHR","HK0000165453.HKD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132454908","title":"特朗普：8月就業數據超預期，要求聯儲局降息","url":"https://stock-news.laohu8.com/highlight/detail?id=1132454908","media":"特朗普社媒动态","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132454908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 21:41","pubTimestamp":1788529306,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".SPX",".IXIC",".DJI","FXR","CLIX","VAW","ANEW","PEVC","TSLP","UCC","KOMP","RJZ","FXL","CAOS","DFUV","CGDV","AVSD","IJK","LRCY","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康寧傑瑞生物製藥回購56,000股 耗資492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664337721?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03069","EWH","CNAV","IBBQ","MRNX","MRNY","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LFSC","IE00B4R5TH58.HKD","LU2322448957.HKD","IE00BJJMRZ35.SGD","BIB","MEDX","BK4588","XPH","IDNA","IE0002141913.USD","RSPH","RXL","PBPH","IBRN","BBP","IE00BJT1NW94.SGD","MRNX","FBT","XBIX","BIOY","BK4585","SBIO","AZNH","PJP","MEDI","TMED","IE00BFTCPJ56.SGD","LU0211331839.USD","HELX","IEIH","FTXH","IBB","LU0070302665.USD","MRNY","IE0009355771.USD","PBE","BK4007","PPH","IEHS","BBH","SYNB","WDNA","CANC","NVS","PSCH","LU2473716301.USD","LU2272731600.USD","BME","IYH","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["APXH","GSKH","BK4585","AGIX","QTOC","WRND","PBE","XLVI","AIPO","BBP","IBB","ARTY","BK4588","BIOY","GDOC","CHAT","VTHR","SBIO","LFSC","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663238000","title":"武漢友芝友生物製藥股份有限公司在香港暫停交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2663238000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663238000?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:36","pubTimestamp":1788136595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","MRNY","IBBQ","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663302804","title":"新股消息 | 貝達藥業(300558.SZ)再度遞表港交所 「四駕馬車」協同打造全產業鏈生物製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2663302804","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663302804?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:14","pubTimestamp":1788135285,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月28日披露，贝达药业股份有限公司向港交所主板提交上市申请，中信证券为其独家保荐人。毛利率于2023年度、2024年度、2025年度及2026年截至6月30日止六个月，公司对应毛利率分别为82.7%、80.5%、78.3%、75.1%。全球及中国的肺癌发病率和死亡率均呈上升趋势。全球肺癌新发病例数从2020 年的230万增至2025年的270万，预计到2035年将增至350万。目前，FDA已批准6种ALK TKI上市，EMA已批准5种ALK TKI上市，国家药监局已批准10种ALK TKI上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03069","300558","MRNY","MRNX","HEXmain","IBBQ","BK0239","IPOS","BK0060","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBB","600513","LFSC","BBP","BK0239","GSKH","BIOY","GDOC","WRND","XLVI","PBE","BK4588","BK4585","SBIO","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662058121","title":"海正藥業與星際開發達成戰略合作 佈局太空生物製藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058121","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662058121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 10:52","pubTimestamp":1787885542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNY","MRNX","IBBQ","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BBP","GSKH","IBB","LFSC","PBE","BK0216","SPHQ","GDOC","BIOY","XLVI","BK4585","APXH","300404","BK4588","WRND","SBIO","159399"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661672552","title":"阿巴斯生物製藥宣佈擬通過改良式「荷蘭拍賣」要約收購，回購最高價值2.3億美元的公司普通股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661672552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661672552?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 19:30","pubTimestamp":1787311853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","EVNT","IBBQ","MRNY","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431564","title":"駿利亨德森投資：專利到期倒逼藥企擴張 生物科技併購、IPO市場同步復甦","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:06","pubTimestamp":1787126785,"startTime":"0","endTime":"0","summary":"骏利亨德森投资称，尽管利率较市场年初的预期为高，但生物科技行业交易活动的增长动力持续不减。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4582","FBT","BIB","PBE","BK4588","BBP","SPCK","QSML","MRNY","GTPE","BIS","BBC","IBBJ","IAI","IJT","BK4585","IYG","JDOC","IWO","MRNX","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660415061","title":"杭蕭鋼構等投資成立生物製藥公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660415061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660415061?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:44","pubTimestamp":1787103899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MRNY","MRNX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601881","BK0188","BBP","WRND","BK4585","161027","PBE","BK4588","APXH","06881","LFSC","BK1147","GSKH","XLVI","SBIO","BK0276","IBB","BIOY","BK1564","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBE","IBB","BIOY","SBIO","BK0102","BK4588","LFSC","BK4585","BK0216","XLVI","WRND","600721","APXH","GSKH","BBP","GDOC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}